Nanovaccines: A game changing approach in the fight against infectious diseases
- PMID: 37783148
- DOI: 10.1016/j.biopha.2023.115597
Nanovaccines: A game changing approach in the fight against infectious diseases
Abstract
The field of nanotechnology has revolutionised global attempts to prevent, treat, and eradicate infectious diseases in the foreseen future. Nanovaccines have proven to be a valuable pawn in this novel technology. Nanovaccines are made up of nanoparticles that are associated with or prepared with components that can stimulate the host's immune system. In addition to their delivery capabilities, the nanocarriers have been demonstrated to possess intrinsic adjuvant properties, working as immune cell stimulators. Thus, nanovaccines have the potential to promote rapid as well as long-lasting humoral and cellular immunity. The nanovaccines have several possible benefits, including site-specific antigen delivery, increased antigen bioavailability, and a diminished adverse effect profile. To avail these benefits, several nanoparticle-based vaccines are being developed, including virus-like particles, liposomes, polymeric nanoparticles, nanogels, lipid nanoparticles, emulsion vaccines, exomes, and inorganic nanoparticles. Inspired by their distinctive properties, researchers are working on the development of nanovaccines for a variety of applications, such as cancer immunotherapy and infectious diseases. Although a few challenges still need to be overcome, such as modulation of the nanoparticle pharmacokinetics to avoid rapid elimination from the bloodstream by the reticuloendothelial system, The future prospects of this technology are also assuring, with multiple options such as personalised vaccines, needle-free formulations, and combination nanovaccines with several promising candidates.
Keywords: Clinical trials; Future direction; Immunity; Infectious diseases; Nanovaccines; Recent advances.
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
The shift toward nanovaccination: A comprehensive review of advancing nanovaccination for combinatory immune regulation therapies to treat infectious diseases and cancer.Int Immunopharmacol. 2025 Aug 28;161:115090. doi: 10.1016/j.intimp.2025.115090. Epub 2025 Jun 16. Int Immunopharmacol. 2025. PMID: 40526984 Review.
-
Nanovehicles for delivery of antigens and adjuvants as cancer nanovaccines.J Mater Chem B. 2025 Jun 4;13(22):6276-6298. doi: 10.1039/d5tb00293a. J Mater Chem B. 2025. PMID: 40356516 Review.
-
Advancements in prophylactic and therapeutic nanovaccines.Acta Biomater. 2020 May;108:1-21. doi: 10.1016/j.actbio.2020.03.020. Epub 2020 Apr 5. Acta Biomater. 2020. PMID: 32268235 Free PMC article. Review.
-
Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.Adv Exp Med Biol. 2021;1295:303-315. doi: 10.1007/978-3-030-58174-9_13. Adv Exp Med Biol. 2021. PMID: 33543465
-
Lymph node-targeting nanovaccines for cancer immunotherapy.J Control Release. 2022 Nov;351:102-122. doi: 10.1016/j.jconrel.2022.09.015. Epub 2022 Sep 20. J Control Release. 2022. PMID: 36115556 Review.
Cited by
-
Concerns regarding the alarming surge in HIV/AIDS cases in Pakistan.Ann Med Surg (Lond). 2024 Jul 23;86(9):4963-4965. doi: 10.1097/MS9.0000000000002400. eCollection 2024 Sep. Ann Med Surg (Lond). 2024. PMID: 39238956 Free PMC article. No abstract available.
-
Healthcare challenges in LMICs: addressing antibiotic resistance threats, a call for comprehensive global solutions: an editorial.Int J Surg. 2024 May 1;110(5):3085-3087. doi: 10.1097/JS9.0000000000001165. Int J Surg. 2024. PMID: 38748502 Free PMC article. No abstract available.
-
Exploring the causal relationships between cholelithiasis, cholecystitis, cholecystectomy, and gastroesophageal reflux disease: a bidirectional two-sample Mendelian randomization study.Int J Surg. 2025 Jan 1;111(1):932-940. doi: 10.1097/JS9.0000000000001992. Int J Surg. 2025. PMID: 39093866 Free PMC article.
-
DNA methylation urine test in the diagnosis of upper tract urothelial carcinoma: a systematic review and meta-analysis.Int J Surg. 2025 Jan 1;111(1):1255-1264. doi: 10.1097/JS9.0000000000001904. Int J Surg. 2025. PMID: 39037716 Free PMC article.
-
Cachexia in tuberculosis in South-East Asian and African regions: knowledge gaps and untapped opportunities.Ann Med Surg (Lond). 2024 Aug 14;86(10):5922-5929. doi: 10.1097/MS9.0000000000002446. eCollection 2024 Oct. Ann Med Surg (Lond). 2024. PMID: 39359826 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical